Document:

<PAGE>

                                                                   Exhibit 10.47

                          CONSULTING SERVICES AGREEMENT

      This Agreement is made as of November 15, 2004 (the "Effective Date"), by
and between Neurocrine Biosciences, Inc., 12790 El Camino Real, San Diego,
California 92130 (the "Company") and Wylie W. Vale, Ph.D., the Salk Institute
for Biological Studies, 10010 North Torrey Pines Road, La Jolla California 92037
(the "Consultant").

      The Consultant has been involved in scientific research of particular
interest to the Company. The Company wishes to retain the Consultant in a
consulting capacity, and the Consultant desires to perform such consulting
services. Accordingly, the parties agree as follows:

1.    Services. The Consultant will advise the Company's management, employees
and agents, at reasonable times, in matters related to the relevant field of
interest, as requested by the Company as set forth below. The field of interest
for consulting hereunder involves the advisory oversight of the Company's
research and development programs including the review of the research programs,
research support for development programs, priorities, staffing and advising the
scientific directors and the Company's President & CEO ("Field of Interest").

2.    Compensation. For services rendered by Consultant to the Company
hereunder, the Company will pay the Consultant $50,000 per year payable
quarterly in advance.

3.    Term. This Agreement supercedes the Consulting Agreement dated November
15, 2003 by and between Consultant and Company. The term of this Agreement will
begin on the Effective Date and will end on November 15, 2005, unless extended
by mutual consent.

4.    Certain other Contracts.

      4.1   Consultant is an employee of The Salk Institute for Biological
Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037 ("The Salk
Institute").

      4.2   Consultant is conducting research at The Salk Institute (the "Salk
Research"), which Salk Research may, in part, overlap with the consulting
services.

      4.3   Consultant is required under The Salk Institute's policies to assign
to The Salk Institute rights to any inventions which are (i) conceived,
developed, made, produced or reduced to practice by Consultant during the course
of the Salk Research, or (ii) involve the use of laboratories, equipment,
materials or other resources, information or trade secrets or other intellectual
property belonging to The Salk Institute.

      4.4   Except for disclosures made pursuant to a confidentiality agreement,
The Salk Institute's scientists are prohibited from disclosing to any commercial
company any information generated in their laboratories at The Salk Institute
prior to publication or to making such information generally available to
members of the research community. The foregoing restriction does not preclude a
scientist from consulting within the general area of research being conducted in
his or her laboratory provided that the assistance and information supplied is
limited to published information and information which is within the general
knowledge of scientists outside The Salk Institute.

      4.5   Consultant acknowledges that he may obtain access to confidential
information regarding research, product developments, preclinical and clinical
studies and results thereof, formulations, inventions, trade secrets, know-how
and other information which is developed by him or by others at The Salk
Institute as proprietary and confidential information (the "Salk Information"),
and that his obligations under his agreement with The Salk Institute prevent him

                                   Page 1 of 5
<PAGE>

from disclosing such Salk Information to Company, except pursuant to a
confidentiality agreement between Company and The Salk Institute.

      4.6   The Consultant has disclosed and, during the Term, will disclose to
the Chief Executive Officer of the Company any conflicts between this Agreement
and any other agreements binding the Consultant.

5.    Exclusive Services During the Term. Subject to written waivers that may be
provided by the Company upon request, the Consultant agrees that during the term
of this Agreement he will not directly or indirectly without the prior written
approval of the Company (i) provide any services in the Field of Interest to any
other business or commercial entity, (ii) participate in the formation of any
business or commercial entity in the Field of Interest, or (iii) solicit or hire
away any employee or consultant of the Company. Consultant shall notify the
Company of all other consulting agreements which Consultant has entered into, or
any consulting services which Consultant may provide, to any third party.

6.    Inventions Discovered by the Consultant While Performing Services
      Hereunder.

      6.1   Subject to the terms of paragraph 6.2, below, the Consultant hereby
assigns to the Company any right, title, and interest he may have in any
invention, discovery, improvement, or other intellectual property which (i) the
Consultant, alone or with others, develops as a direct result of performing
consulting services for the Company under this Agreement and (ii) is not
developed in the course of Consultant's activities as a Salk Institute employee
and is not owned by or assignable to The Salk Institute. Any intellectual
property assignable to the Company pursuant to the preceding sentence is
hereinafter referred to as "Company Intellectual Property". Upon the request of
the Company, the Consultant shall execute such further assignments, documents,
and other instruments as may be necessary to assign Company Intellectual
Property to the Company and to assist the Company in applying for, obtaining and
enforcing patents or other rights in the United States and in any foreign
country with respect to any Company Intellectual Property. The Company will bear
the cost of preparation of all patent or other applications and assignment, and
the cost of obtaining and enforcing all patents and other rights to Company
Intellectual Property.

      6.2   The Company shall have no rights by reason of this Agreement in any
publication, invention, discovery, improvement, or other intellectual property
whatsoever, whether or not publishable, patentable, or copyrightable, which is
developed as a result of a program of research financed, in whole or in part, by
funds provided by or under the control of The Salk Institute. The Company also
acknowledges and agrees that it will enjoy no priority or advantage as a result
of the consultancy created by this Agreement in gaining access, whether by
license or otherwise, to any proprietary information or intellectual property
that arises from any research undertaken by the Consultant in his capacity as an
employee of The Salk Institute.

7.    Confidentiality.

      7.1   The Consultant acknowledges that, during the course of performing
his services hereunder, the Company will be disclosing information to the
Consultant, and the Consultant will be developing information related to the
Field of Interest, Company Intellectual Property, projects, products, potential
customers, personnel, business plans, and finances, as well as other
commercially valuable information (collectively "Confidential Information"). The
Consultant acknowledges that the Company's business is extremely competitive,
dependent in part upon the maintenance of secrecy, and that any disclosure of
the Confidential Information would result in serious harm to the Company.

      7.2   The Consultant agrees that the Confidential Information will be used
by the Consultant only in connection with consulting activities hereunder, and
will not be used in any way that is detrimental to the Company.

                                   Page 2 of 5
<PAGE>

      7.3   The Consultant agrees not to disclose, directly or indirectly, the
Confidential Information to any third person or entity, other than
representatives or agents of the Company. The Consultant will treat all such
Confidential Information as confidential and proprietary property of the
Company.

      7.4   Confidential Information subject to paragraphs 7.1-7.3 do not
include information that: (i) is or later becomes available to the public
through no breach of this Agreement by the Consultant; (ii) is obtained by the
Consultant from a third party who had the legal right to disclose the
information to the Consultant; (iii) is already in the possession of the
Consultant on the date this Agreement becomes effective; or (iv) is required to
be disclosed by law, government regulation, or court order. In addition,
Confidential Information subject to paragraphs 7.1-7.3 do not include
information generated by the Consultant, alone or with others, unless the
information (I) is generated solely as a direct result of the performance of the
consulting services under this Agreement and (II) is not generated in the course
of the Consultant's activities as a Salk Institute employee.

      7.5   The Consultant may disclose to the Company any information that the
Consultant would normally freely disclose to other members of the scientific
community at large, whether by publication, by presentation at seminars, or in
informal scientific discussions. However, the Consultant shall not disclose to
the Company information that is proprietary to The Salk Institute and is not
generally available to the public other than through formal technology transfer
procedures.

      7.6   Upon termination of this Agreement, if requested to do so by the
Company, the Consultant will promptly return to the Company all materials
containing Confidential Information as well as data, records, reports and other
property, furnished by the Company to the Consultant or produced by the
Consultant in connection with services rendered hereunder, together with all
copies of any of the foregoing. Notwithstanding any such return, the Consultant
shall continue to be bound by the terms of the confidentiality provisions
contained in this Section 7 for a period of five years after the termination of
this Agreement.

8.    Freedom to Publish and Academic Obligations.

      8.1   Company acknowledges that Consultant is conducting and will in the
future conduct Salk Research. Company agrees that the provisions of this
Agreement will not restrict Consultant's right to lecture upon, publish or
otherwise disseminate results of the Salk Research (collectively referred to as
"Permitted Disclosures"), even though the Permitted Disclosures may be related
to the subject matter of this Agreement; provided that such Permitted Disclosure
includes no Confidential Information of Company. However, Consultant will review
with The Salk Institute in advance of such publication or dissemination said
Permitted Disclosures in order to evaluate the need to file a patent
application.

      8.2   It is understood that Consultant is a member of the faculty of The
Salk Institute and that, as such, Consultant must fulfill certain obligations to
The Salk Institute, including, among other things, teaching, conducting Salk
Research, publishing and interacting with investigators at other academic,
research and commercial institutions. Accordingly, it is agreed that
Consultant's consulting obligations to Company will be subject to the foregoing
obligations to The Salk Institute. Company recognizes and acknowledges that
Consultant is currently employed by, and Consultant's primary responsibilities
are to, The Salk Institute. Company further acknowledges that, in connection
with such employment, Consultant has entered into certain agreements with The
Salk Institute relating to the ownership of intellectual property rights,
conflicts of interest and other matters and are subject to certain policy
statements of The Salk Institute (the "Institutional Agreements"). Company and
Consultant both recognize and acknowledge that Consultant remains obligated to
comply with such Institutional Agreements and written regulations and policies
of The Salk Institute. Consultant hereby represents that nothing in the
Institutional Agreements are in conflict with the terms of this Agreement.

                                   Page 3 of 5
<PAGE>

      8.3   Nothing in this Agreement shall be deemed to give Company any rights
in or to any intellectual property rights of The Salk Institute. Company
acknowledges that any commercialization of any intellectual property resulting
from the Salk Research would require Company to obtain rights to such
intellectual property developed or to be developed by Consultant or others in
Consultant's laboratory at The Salk Institute, the rights to which are held by
The Salk Institute.

      8.4   The Company acknowledges and agrees that nothing in this Agreement
shall affect the Consultant's obligations to, or research on behalf of, The Salk
Institute, including, without limitation, obligations or research of the
Consultant in connection with a transfer by The Salk Institute of materials or
intellectual property developed in whole or in part by the Consultant, or in
connection with research collaborations.

9.    No Conflict: Valid and Binding. The Consultant represents that neither the
execution of this Agreement nor the performance of the Consultant's obligations
under this Agreement will result in a violation or breach of any other agreement
by which the Consultant is bound. The Company represents that this Agreement has
been duly authorized and executed and is a valid and legally binding obligation
of the Company, subject to no conflicting agreements.

10.   Defense and Indemnification. The Company agrees, at its sole expense, to
defend the Consultant against, and to indemnify and hold the Consultant harmless
from, any claims or suits by a third party against the Consultant or any
liabilities or judgments based thereon, either arising from this Agreement, the
Consultant's performance of services for the Company under this Agreement, or
any Company products which result from the Consultant's performance of services
under this Agreement.

11.   Notices. Any notice provided under this Agreement shall be in writing and
shall be deemed to have been effectively given (i) upon receipt when delivered
personally, (ii) one day after sending when sent by private express mail service
(such as Federal Express), or (iii) 5 days after sending when sent by regular
mail to the following address:

      In the case of the Company:

            Kevin C. Gorman, Ph.D.
            Vice President Business Development
            Neurocrine Biosciences, Inc.
            12790 El Camino Real
            San Diego CA  92130

      cc:   Corporate Secretary

      In the case of the Consultant:

            Dr. Wylie Vale
            The Clayton Foundation Laboratories
            The Salk Institute
            10010 N. Torrey Pines Road
            La Jolla, CA 92037

or to other such address as may have been designated by the Company or the
Consultant by notice to the other given as provided herein.

12.   Independent Contractor: Withholdings. The Consultant will at all times be
an independent contractor, and as such will not have authority to bind the
Company. The

                                  Page 4 of 5
<PAGE>

Consultant will not act as an agent nor shall he be deemed to be an employee of
the Company for the purposes of any employee benefit program, unemployment
benefits, or otherwise. The Consultant recognizes that no amount will be
withheld from his compensation for payment of any federal, state, or local taxes
and that the Consultant has sole responsibility to pay such taxes, if any, and
file such returns as shall be required by applicable laws and regulations.
Consultant shall not enter into any agreements or incur any obligations on
behalf of the Company.

13.   Assignment. Due to the personal nature of the services to be rendered by
the Consultant, the Consultant may not assign this Agreement. The Company may
assign all rights and liabilities under this Agreement to a subsidiary or an
affiliate or to a successor to all or a substantial part of its business and
assets without the consent of the Consultant. Subject to the foregoing, this
Agreement will inure to the benefit of and be binding upon each of the heirs,
assigns and successors of the respective parties.

14.   Severability. If any provision of this Agreement shall be declared
invalid, illegal or unenforceable, such provision shall be severed and the
remaining provisions shall continue in full force and effect.

15.   Remedies. The Consultant acknowledges that the Company would have no
adequate remedy at law to enforce Section 7 of this Agreement. In the event of a
violation by the Consultant of this Section, the Company shall have the right to
obtain injunctive or other similar relief, as well as any relevant damages,
without the requirement of posting bond or other similar measures.

16.   Governing Law; Entire Agreement. This Agreement shall be governed by the
laws of the State of California applicable to agreements made and to be
performed within such State, represents the entire understanding of the parties,
supersedes all prior agreements between the parties, and may only be amended in
writing.

      IN WITNESS WHEREOF, the parties have executed this Agreement as of the
dates set forth below.

NEUROCRINE BIOSCIENCES, INC.                      CONSULTANT

                                                  /s/ Wylie Vale
By: /s/ Gary A. Lyons                             --------------------------
    -------------------------------               Wylie Vale, Ph.D.
    Gary A. Lyons

Title: President & CEO

                                   Page 5 of 5<PAGE>

                                                                   Exhibit 10.48

                          CONSULTING SERVICES AGREEMENT

      This Consulting Services Agreement (this "Agreement") is made November 15,
2004 ("Effective Date") by and between Lawrence Steinman, M.D., Department of
Neurology & Neurological Sciences, 300 Pasteur Drive, B002 Beckman Center,
Stanford, California 94503-5429 ("Consultant") and Neurocrine Biosciences, Inc.,
12790 El Camino Real, San Diego, California 92130 ("Neurocrine").

      WHEREAS, Neurocrine is engaged in the research and development of human
pharmaceutical products;

      WHEREAS, Consultant has experience in research and development (the
"Field");

      WHEREAS, Neurocrine wishes to engage the Consultant to provide the
Services set forth below on the terms and conditions set forth herein and the
Consultant wishes to be so retained;

      NOW THEREFORE, in consideration of the premises and of the mutual
covenants, conditions and agreements contained herein, the parties agree as
follows:

                                   ARTICLE ONE
                               CONSULTING SERVICES

1.1   ENGAGEMENT. Neurocrine hereby agrees to engage the Consultant to perform
the Services set forth in paragraph 1.2 hereof for the benefit of Neurocrine and
the Consultant agrees to perform such Services on the terms and conditions set
forth herein.

1.2   SERVICES TO BE PERFORMED BY CONSULTANT. During the term of this Agreement,
Consultant shall, under the direction of Wendell Wierenga, Executive Vice
President, Research and Development, perform the Services set forth below
(collectively, the "Services"). Consultant shall:

      (a) as a founding member of Neurocrine's Scientific Advisory Board,
consult on matters relating to research and development; and

      (b) such additional Services as mutually agreed upon by the parties.

1.3   REPORTING. Neurocrine shall have the right to request written reports at
any time during the term of this Agreement describing the progress, status of,
data, costs and other matters pertaining to the Services as Neurocrine shall
request. All such information arising out of the performance of the Services
under this Agreement may be freely utilized by Neurocrine in any manner desired.

1.4   LOCATION. The Services shall be performed at such place or places and at
such time or times as Neurocrine and Consultant shall reasonably agree.

                                      -1-
<PAGE>

                                   ARTICLE TWO
                                  COMPENSATION

2.1   COMPENSATION. The Consultant will be paid forty thousand dollars
($40,000.00) per year for all services rendered hereunder payable. This fee will
be payable on installments of ten thousand dollars ($10,000) per quarter in
advance on the first day of each calendar quarter.

2.2   REIMBURSEMENT. Neurocrine will reimburse Consultant for any and all
reasonable travel related expenses incurred by Consultant in connection with
Consultant's performance of the Services, provided, however, that all such
expenses must be preapproved by Neurocrine in writing. Reimbursement for travel
related expenses will not include routine travel to and from work. Reimbursable
travel expenses shall include automobile rental and other transportation
expenses, hotel expenses and meals. All requests for reimbursement for
travel-related expenses must be accompanied by documentation in form and detail
sufficient to meet the requirements of the taxing authorities with respect to
recognition of business-related travel expenses for corporate tax purposes.

                                  ARTICLE THREE
                            WARRANTIES AND COVENANTS

3.1   CONSULTANT'S WARRANTIES. The Consultant represents and warrants:

      (a) Consultant has not entered into any agreement, whether written or
oral, in conflict with this Agreement; and

      (b) Consultant has the full power and authority to enter into this
Agreement.

3.2   CONSULTANT'S COVENANTS. Consultant:

      (a) shall act as an independent contractor with no authority to obligate
Neurocrine by contract or otherwise and not as an employee or officer of
Neurocrine;

      (b) shall exercise only such powers and perform such duties as may from
time to time be vested in Consultant or assigned to Consultant by Neurocrine;

      (c) shall perform the Services and promote the interests of Neurocrine to
the best of Consultant's skill and ability;

      (d) shall comply with all standards of safety, take due regard and comply
with the safety regulations of Neurocrine and all statutory provisions in effect
and report to Neurocrine any incident which could give rise to unsafe working
conditions or practices;

      (e) shall not assign or subcontract performance of this Agreement or any
of the Services to any person, firm, company or organization without
Neurocrine's prior written consent;

      (f) shall not recruit, solicit or induce any Neurocrine employee, client,
customer or account to terminate their employment or relationship with
Neurocrine;

                                      -2-
<PAGE>

      (g) shall not initiate or participate in any communications with the
United States Food and Drug Administration, other governmental agency or foreign
equivalent concerning the subject matter hereof unless required by law or
requested to do so by Neurocrine and ,then, only upon prior consultation with
Neurocrine;

      (h) shall not, during the term of this Agreement, enter into any other
agreement, whether written or oral, which would conflict with Consultant's
obligations hereunder or engage in any activity which relates to a business
directly competing or attempting to directly compete with Neurocrine; and

      (i) provided, however, that the above shall not prevent the Consultant
from engaging in any academic research, teaching or related non-commercial
activity.

                                  ARTICLE FOUR
                            CONFIDENTIAL INFORMATION

4.1   CONFIDENTIALITY. Consultant shall, during the term of this Agreement and
for a period of five (5) years thereafter, keep all Neurocrine Confidential
Information confidential and use such information only for the purposes
expressly set forth herein. Neurocrine Confidential Information shall mean all
information concerning Neurocrine or the Field which is disclosed to Consultant
by Neurocrine or which results from, or in connection with, any Services
performed pursuant to this Agreement. Such information includes, but is not
limited to, confidential or proprietary information, materials, know-how and
other data, both technical and nontechnical.

4.2   ACCESS. Consultant agrees to limit the access to Neurocrine Confidential
Information to only those persons under Consultant's direct control who, with
Neurocrine's knowledge and consent, are responsible for performing the Services
set forth in Article One.

4.3   AUTHORIZED DISCLOSURE. Consultant shall have no obligation of
confidentiality and non-use with respect to any portion of Neurocrine
Confidential Information which (i) is or later becomes generally available to
the public by use, publication or the like, through no act or omission of
Consultant; (ii) is obtained from a third party who had the legal right to
disclose the information to Consultant; or (iii) Consultant already possesses as
evidenced by Consultant's written records predating receipt thereof from
Neurocrine.

4.4   RETURN OF INFORMATION. Upon the termination of this Agreement, Consultant
will promptly return to Neurocrine all materials, records, documents, and other
Neurocrine Confidential Information in tangible form. Consultant shall retain no
copies of such materials and information and, if requested by Neurocrine, will
delete all Neurocrine Confidential Information stored in any magnetic or optical
disc or memory.

4.5   THIRD PARTY INFORMATION. Consultant shall not, in connection with the
Services to be performed under this Agreement, disclose to Neurocrine any
information which is confidential or proprietary to Consultant or any third
party.

                                      -3-
<PAGE>

                                  ARTICLE FIVE
                              INTELLECTUAL PROPERTY

5.1   OWNERSHIP. Consultant agrees that any information, including but not
limited to discoveries, inventions, copyright, design rights, patents,
innovations, suggestions, know-how, ideas and reports made by Consultant to
Neurocrine which result from, or are related to, information disclosed by
Neurocrine to Consultant or which are developed as a result of, or in connection
with, Consultant's Services under this Agreement shall be promptly disclosed to
Neurocrine and treated by Consultant as the sole property of Neurocrine
("Neurocrine Intellectual Property").

5.2   ASSIGNMENT. Consultant agrees to assign to Neurocrine any rights that
Consultant may acquire, any Neurocrine Intellectual Property, and further agrees
to assist Neurocrine (at Neurocrine's expense) in obtaining, enforcing and
maintaining Neurocrine's rights in and to the Neurocrine Intellectual Property
and irrevocably appoints Neurocrine and its duly authorized officers and agents
as his agents and attorneys for such purpose.

                                   ARTICLE SIX
                           RELATIONSHIP OF THE PARTIES

6.1   RELATIONSHIP. The relationship of Consultant to Neurocrine will be one of
independent contractor and at no time will Contractor hold itself out to be an
employee of Neurocrine or represent itself, either directly or indirectly, as
being connected with or interested in the business of Neurocrine.

6.2   NO WITHHOLDING. No amount will be deducted or withheld from Neurocrine's
payment to Consultant for state, federal or local taxes. No FICA, FUTA, SDI or
state unemployment taxes will be payable by Neurocrine on Consultant's behalf
and Consultant will be solely responsible for and will pay such taxes.

6.3   BENEFITS. Consultant shall not claim the status, prerequisites or benefits
of an Neurocrine employee. Consultant agrees that Consultant is not eligible for
coverage or to receive any benefit under any Neurocrine employee benefit plan or
employee compensation arrangement, including without limitation, any and all
medical and dental plans, bonus or incentive plans, retirement benefit plans,
stock plans, disability benefit plans, life insurance and any and all other such
plans or benefits. Even if Consultant were to become or be deemed to be a
common-law employee of Neurocrine, Consultant still shall not be eligible for
coverage or to receive any benefit under any Neurocrine employee benefit plan or
any employee compensation arrangement with respect to any period during which
Neurocrine classified the individual as a Consultant.

6.4   INDEMNIFICATION. This Agreement constitutes a contract for the provision
of Services and not a contract for employment and, accordingly, Consultant will
be fully responsible for and will indemnify Neurocrine for and in respect of any
state, local or federal taxes or fees including without limitation, income tax
withholding, employment and self-employment taxes, FUTA, SDI and state
unemployment taxes together with any other liability, deduction, contribution,
assessment or claim arising from or made in connection with the performance by
Neurocrine of its obligations under this Agreement or the performance by the
Consultant of the

                                      -4-
<PAGE>

Services. The Consultant will further indemnify Neurocrine against all
reasonable costs and expenses and any penalty, fine or interest incurred or
payable by Neurocrine in connection with or in consequence of such liability,
deduction, contribution, assessment or claim. Neurocrine may, at its option,
satisfy such indemnity (in whole or in part) by way of deduction from the fees
and/or expenses payable by Neurocrine to Consultant hereunder.

6.5   WORKER'S COMPENSATION. Consultant acknowledges that if Consultant is
injured while performing work for Neurocrine hereunder, Consultant will not be
covered for such injury under Neurocrine's insurance policies, including under
any Worker's Compensation coverage provided for Neurocrine's employees and
further acknowledges that Consultant is solely responsible for providing
Worker's Compensation insurance for Consultant and Consultant's employees.

                                  ARTICLE SEVEN
                              TERM AND TERMINATION

7.1   TERM. This Agreement shall terminate one (1) year from the Effective Date.
At the end of the one (1) year term, this Agreement may be renewed on equivalent
terms and conditions upon the mutual written consent of the parties.

7.2   TERMINATION. This Agreement may be terminated by either party at any time
upon written notice to the other party. In the event this Agreement shall be so
terminated by either party, upon submission to Neurocrine by Consultant of
reasonable documentation of all work performed by Consultant to such date,
Consultant shall be entitled to recover payment for all work actually performed
prior to the date of termination.

7.3   EFFECT OF TERMINATION. Upon the termination of this Agreement, each party
shall be released from all obligations and liabilities hereunder except those
arising under Articles Four and Five.

                                  ARTICLE EIGHT
                                  MISCELLANEOUS

8.1   WAIVER. None of the terms of this Agreement may be waived except by an
express agreement in writing signed by the party against whom enforcement of
such waiver is sought. The failure or delay of either party in enforcing any of
its rights under this Agreement shall not be deemed a continuing waiver of such
right.

8.2   ENTIRE AGREEMENT. This Agreement constitutes the entire agreement among
the parties with respect to the subject matter hereof and supersedes all prior
agreements and understandings among the parties (whether written or oral)
relating to said subject matter.

8.3   AMENDMENTS. This Agreement may not be released, discharged, amended or
modified in any manner except by an instrument in writing signed by Consultant
and a duly authorized officer of Neurocrine.

                                      -5-
<PAGE>

8.4   ASSIGNMENT. Neurocrine has specifically contracted for the Services of
Consultant and, therefore, Consultant may not assign or delegate Consultant's
obligations under this Agreement, either in whole or in part, without the prior
written consent of Neurocrine. Neurocrine may assign this Agreement at any time
without the prior consent of Consultant.

8.5   SEVERABILITY. If any provision of this Agreement is, becomes, or is deemed
invalid, illegal or unenforceable in any jurisdiction, such provision shall be
deemed amended to conform to the applicable laws so as to be valid and
enforceable, or, if it can not be so amended without materially altering the
intention of the parties hereto, it shall be stricken and the remainder of this
Agreement shall remain in full force and effect.

8.6   HEADINGS. Article and Section headings contained in the Agreement are
included for convenience only and are not to be used in construing or
interpreting this Agreement.

8.7   COUNTERPARTS. This Agreement may be executed in any number of
counterparts, each of which shall be an original and all of which together shall
constitute one and the same document, binding on all parties notwithstanding
that each of the parties may have signed different counterparts.

8.8   GOVERNING LAW. This Agreement shall be governed by and construed in
accordance with the laws of the state of California and the parties to this
Agreement hereby submit to the exclusive jurisdiction of the California courts,
both state and federal.

8.9   PUBLIC ANNOUNCEMENTS. Consultant may not make any press release, statement
or public announcement that mentions or refers to Neurocrine without
Neurocrine's prior written consent.

8.10  EMPLOYMENT. Consultant certifies that Services furnished under this
Agreement have been furnished in full compliance with all applicable federal and
state laws and regulations relating to nondiscrimination in employment.
Consultant certifies that it does not maintain any segregated facilities.

8.11  OTHER. This Agreement supersedes the Agreement dated November 15, 2003
between Neurocrine and the Consultant.

IN WITNESS WHEREOF, the parties have entered into this Agreement on the date
first above written.

                                 CONSULTANT

                                 /s/ Lawrence Steinman, M.D.
                                 -------------------------------------
                                 Lawrence Steinman, M.D.

                                 NEUROCRINE BIOSCIENCES, INC.

                                 /s/Margaret Valeur-Jensen
                                 -------------------------------------
                                 By:    Margaret Valeur-Jensen
                                 Title: Senior Vice President

                                      -6-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00078-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00078-of-00352.parquet"}]]